Gilead drug modestly delays breast cancer progression in late-stage trial

Published by

By Deena Beasley (Reuters) – Gilead Sciences Inc’s Trodelvy extended by 1.5 months, or 34%, the length of time women with advanced stages of the most common type of breast cancer lived without their disease worsening, according to late-stage trial data presented on Saturday. The Phase III study compared Trodelvy to chemotherapy in 543 patients with hormone-sensitive tumors that test negative for a receptor called HER2 and who had stopped responding to at least two earlier lines of therapy. The data, presented in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO),…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street